Minneapolis Portfolio Management Group LLC boosted its stake in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 233.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 303,853 shares of the company’s stock after acquiring an additional 212,691 shares during the quarter. Zoetis accounts for 1.9% of Minneapolis Portfolio Management Group LLC’s portfolio, making the stock its 27th largest position. Minneapolis Portfolio Management Group LLC’s holdings in Zoetis were worth $21,218,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in shares of Zoetis by 10.8% in the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after purchasing an additional 3,845,869 shares in the last quarter. State Street Corp grew its holdings in shares of Zoetis by 1.8% in the 2nd quarter. State Street Corp now owns 19,667,723 shares of the company’s stock worth $1,413,323,000 after purchasing an additional 343,322 shares during the last quarter. Deutsche Bank AG grew its holdings in shares of Zoetis by 5.8% in the 2nd quarter. Deutsche Bank AG now owns 5,851,737 shares of the company’s stock worth $420,506,000 after purchasing an additional 319,709 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Zoetis by 7.3% in the 1st quarter. Bank of America Corp DE now owns 4,831,652 shares of the company’s stock worth $571,150,000 after purchasing an additional 327,313 shares during the last quarter. Finally, Van ECK Associates Corp increased its position in shares of Zoetis by 7.7% during the 2nd quarter. Van ECK Associates Corp now owns 4,252,140 shares of the company’s stock worth $305,559,000 after purchasing an additional 303,395 shares in the last quarter. 92.80% of the stock is owned by institutional investors.
Zoetis Price Performance
Zoetis stock opened at $83.65 on Monday. The business’s fifty day moving average is $76.28 and its two-hundred day moving average is $91.56. The company has a debt-to-equity ratio of 2.51, a quick ratio of 1.40 and a current ratio of 2.35. The firm has a market cap of $33.99 billion, a P/E ratio of 14.23, a P/E/G ratio of 1.21 and a beta of 0.67. Zoetis Inc. has a 52 week low of $68.77 and a 52 week high of $132.49.
Zoetis (NYSE:ZTS – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $1.75 earnings per share for the quarter, beating analysts’ consensus estimates of $1.51 by $0.24. Zoetis had a return on equity of 85.90% and a net margin of 26.15%. The company had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same period last year, the company posted $1.70 earnings per share. The firm’s quarterly revenue was down 1.3% compared to the same quarter last year. Equities research analysts forecast that Zoetis Inc. will post 6.29 earnings per share for the current fiscal year.
Zoetis Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be given a dividend of $0.53 per share. The ex-dividend date is Friday, October 30th. This represents a $2.12 annualized dividend and a yield of 2.5%. Zoetis’s dividend payout ratio is 36.05%.
Analyst Ratings Changes
ZTS has been the subject of several analyst reports. Jefferies Financial Group lifted their price target on shares of Zoetis from $83.00 to $85.00 in a report on Friday, November 6th. Morgan Stanley reduced their price target on shares of Zoetis from $85.00 to $82.00 and set an “overweight” rating on the stock in a research report on Thursday, October 29th. Cantor Fitzgerald set a $94.00 price objective on shares of Zoetis in a research note on Tuesday, August 25th. JPMorgan Chase & Co. dropped their price objective on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, August 7th. Finally, BTIG Research dropped coverage on shares of Zoetis in a research note on Friday, October 30th. They issued a “buy” rating and a $200.00 target price for the company. Eight research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Hold” and an average price target of $101.25.
Check Out Our Latest Report on Zoetis
Zoetis Company Profile
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
Featured Stories
- Five stocks we like better than Zoetis
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
